Replies to post #143893 on Biotech Values

[DewDiligence]

TEVA’s new data on thrice-weekly Copaxone are no big deal insofar as the comparator is placebo:

http://finance.yahoo.com/news/teva-present-positive-data-glatiramer-060000096.html

Teva will never run a head-to-head trial of thrice-weekly vs regular Copaxone.

See #msg-77016146, #msg-63817727, and #msg-76644423 for background.